ABEC Develops Single-Use Bioreactor for Emergent Manufacturing Facility
ABEC, an equipment and engineering company, will provide a custom-made, single-use bioreactor to custom manufacturing firm, Emergent, for its Maryland manufacturing facility.
On Oct. 24, 2017, ABEC, a provider of engineering, equipment, and services to the biopharmaceutical manufacturing sector, announced that Emergent BioSolutions, a provider of contract manufacturing services, will equip its bulk manufacturing facility in Bayview, Baltimore, MD, with an ABEC 4,000-L custom single run (CSR) bioreactor.
The 4,000-L bioreactor will be designed specifically for Emergent’s process needs, operational requirements, and facility constraints, and will expand cell culture capacity at the Bayview site. The system can also deliver performance comparable to stainless steel systems, can be customized for different products, and is anticipated to improve cell culture productivity, process transfer, and scale-up, according to ABEC.
“ABEC’s CSR enables us to fully realize the benefits of single-use technology by improving flexibility while leveraging economies of scale,” said Scott Battist, Emergent BioSolutions’ vice president and general manager of the Bayview site, in a company press release.
Source: ABEC
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
